Chris P Conlon FRCP
Professor of Infectious Diseases
- Head of NDM Experimental Medicine
- Member of congregation
- Group Head / PI
- Consultant Physician and Unit Director
I am responsible for a mixture of clinical, teaching, research and administrative duties, including covering the 18 bed Infectious Diseases Unit at the Churchill Hospital. I collaborate with colleagues in HIV research and am currently on the trial steering committee of the RIVER study; a proof of principle trial of HDAC inhibitors and HIV vaccine use in an attempt to ‘cure’ HIV. I also run the TB service in Oxford and collaborate with Professor Derrick Crook and others using whole genome sequencing to improve diagnoses. I also have oversight of the Tropical Medicine Group and was recently invited to lecture at The First Beijing International Conference on Precision Medicine and Cancer Treatment Forum with a talk entitled “Medical Education in the 21st Century”
I am a Fellow and Tutor in Clinical Medicine at Oriel College, Oxford and regularly teach Oxford medical undergraduates in lectures and seminars, and at the bedside. In addition, I am a Principal Examiner in Medicine in Oxford and Chair of the Royal College of Physicians Joint Specialty Committee for Infectious Diseases.
I was Interim Head of Department for the Nuffield Department of Medicine from May 2016 until June 2019. I have also been the Head NDM Experimental Medicine since 2014.
A simple, robust flow cytometry-based whole blood assay for investigating sex differential interferon alpha production by plasmacytoid dendritic cells.
Sampson O. et al, (2022), J Immunol Methods, 504
Divergent trajectories of antiviral memory after SARS-CoV-2 infection
Tomic A. et al, (2022), Nature Communications, 13
Comparison of two T cell assays to evaluate T cell responses to SARS-CoV-2 following vaccination in naïve and convalescent healthcare workers
Phillips E. et al, (2022)
A haemagglutination test for rapid detection of antibodies to SARS-CoV-2
Townsend A. et al, (2021), Nature Communications, 12
Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern.
Skelly DT. et al, (2021), Nature communications, 12